Free US stock ESG scoring and sustainability analysis for responsible investing considerations. We evaluate environmental, social, and governance factors that increasingly impact long-term company performance.
This analysis covers the April 24, 2026 announcement that Bristol Myers Squibb (NYSE: BMY) and co-marketing partner Pfizer (NYSE: PFE) will list their top-selling anticoagulant Eliquis on the Mark Cuban Cost Plus Drug Company (MCCPDC) platform starting the following week, priced at $345 for a 30-day
Bristol Myers Squibb (BMY) - Partners With Pfizer to List Blockbuster Anticoagulant Eliquis on Mark Cuban Cost Plus Platform at $345 Monthly - Bond Issuance
BMY - Stock Analysis
4354 Comments
719 Likes
1
Hans
Senior Contributor
2 hours ago
I read this and now I’m thinking differently.
👍 273
Reply
2
Loranza
Returning User
5 hours ago
Real-time US stock news flow and impact analysis to understand how current events affect your portfolio holdings. Our news aggregation system filters through thousands of sources to bring you the most relevant information quickly.
👍 264
Reply
3
Mahjabeen
Consistent User
1 day ago
Regret missing this earlier. 😭
👍 135
Reply
4
Armine
Engaged Reader
1 day ago
Offers a clear explanation of potential market scenarios.
👍 17
Reply
5
Icesys
New Visitor
2 days ago
This feels like a turning point.
👍 29
Reply
© 2026 Market Analysis. All data is for informational purposes only.